GT Biopharma, Inc. GTBP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
GT Biopharma, Inc. (GTBP) is a healthcare company listed in the US with a market value of about $8M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -134%.
About GT Biopharma
GT Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 10 years in our data. Its share count rose by 419% over three years (dilution for shareholders).
Score: 1.0 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | — | $0 | — |
| Net income | -$28M | -$13M | -$8M | -$21M | -$58M | -$28M | -$39M | -$259M | -$144M | $10M |
| Free cash flow | — | — | — | — | — | — | -$4M | -$11M | -$5M | -$2M |
| EPS (diluted) | $-6.68 | $-6.94 | $-5.64 | $-19.66 | $-2.06 | $-6.45 | $-0.01 | $-0.09 | $-0.15 | $2038.52 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -169.6% | — | -16.4% | -141.0% | -207.1% | -384.7% | — | -2199.4% | -53.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does GT Biopharma pay a dividend?
Not currently.
Is GT Biopharma a good stock to buy?
We do not give buy or sell advice. GT Biopharma scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.